AB0465 EFFICACY AND SAFETY OF LOW-DOSE IL-2 IN PATIENTS WITH RHEUMATOID ARTHRITIS
Q. Y. Su,X. M. Wang,J. X. Zhang,C. R. Bai,P. H. Chai,Q. Yu,P. F. He,X. LI,S. X. Zhang
DOI: https://doi.org/10.1136/annrheumdis-2023-eular.5223
2023-01-01
Abstract:Background Interleukin (IL)-2 is a key cytokine for tipping the balance of Treg and effector T cells, which can effectively relieve rheumatoid arthritis(RA). Objectives This study aimed to systematically evaluate the efficacy and safety of low-dose IL-2 therapy in RA. Methods Systematic searches of PubMed, EMBASE, Web of Science, the Cochrane Library and Medline, CNKI, CBM, and Technology Journal Database were performed. Original case reports, case series, observational studies, and clinical trials reporting the efficacy or safety data on RA patients treated with IL-2 were included. A random-effects meta-analysis was performed to calculate the pooled efficacy. Inconsistency was evaluated by using the I[2], and Egger tests were used for the evaluation of potential publication bias (STATA v.12.0) Results Thirteen studies comprising 1161 patients were identified (Table 1). After the low-dose IL-2 treatment, there were significant decreases in diseases activity measures such a DAS28[SMD=- 2.631, 95%CI (-3.526,-1.737), P<0.001], SJC[SMD=- 1.066, 95%CI (-1.467,-0.664), P<0.001], TJC[SMD=- 1.032, 95%CI (-1.193,-0.871), P<0.001], ESR[SMD=- 1.315, 95%CI (-1.883,-0.748), P<0.001], and CRP [SMD=- 0.824, 95%CI (-0.997,-0.652), P<0.001]. The values of BUN were increasedand the values of Cr was no statistical differences. The value of ALT was increased while the value of AST was decreased.Blood cell counts such as WBC, PLT and LY were significantly increased and RBC was no statistical difference. Meanwhile, the value of Hb was also no statistical difference(Figure 1). Besides, the numbers of CD4+T cells, CD8+T cells, Th1 cells, Th2 cells, Th17 cells and Tregs were significantly increased after IL-2 injection [SMD=0.819, 95%CI (0.692,0.946), P<0.001; SMD=0.388, 95%CI(0.222,0.554), P<0.001;SMD=0.634, 95%CI (0.436,0.832), P<0.001; SMD=0.521, 95%CI(0.366,0.676), P<0.001;SMD=0.626, 95%CI (0.475,0.776), P<0.001; SMD=1.177, 95%CI(0.941,1.412), P<0.001], while there were no statistical differences in the number of NK cells after IL-2 treatment.Importantly,the ratio of Th17/Tregs was significantly decreased[SMD=-0.700, 95%CI (-0.852,-0.549), P<0.001] and the radio of Th1/Th2 was no statistical difference(Figure 2).After the low-dose IL-2 treatment,the serious adverse event rate reported among all these studies was 0.083 (95%CI 0.051-0.114)(Figure 3). Conclusion Low-dose IL-2 was promising and well-tolerated in the treatment of RA, which could promote the proliferation and functional recovery of Tregs. Acknowledgements This work was supported by the National Natural Science Foundation of China (No. 82001740). Disclosure of Interests None Declared.